Agenus stock falls on profit-taking after Phase 3 financing
Agenus Inc. shares declined on Tuesday due to profit-taking, despite HC Wainwright raising its price target to $30. The company reported durable Phase 1b survival data and secured up to $340 million in private placement financing to advance its Phase 3 ROBBIN trial. Short interest rose to 14.58% of the float.
*this image is generated using AI for illustrative purposes only.
Agenus Inc. shares declined on Tuesday due to profit-taking after a record surge, even as HC Wainwright & Co. maintained its Buy rating and raised its price target to $30. The stock had gained between 95% and 111% on Monday following the release of clinical data and a financing announcement. Short interest increased to 5.99 million shares, representing 14.58% of the public float, with days to cover at 5.42.
Phase 1b Data and Financing
Agenus reported updated three-year Phase 1b data for its botensilimab plus balstilimab combination in 123 patients with refractory microsatellite-stable metastatic colorectal cancer. The combination produced a median overall survival of 21.2 months, with 24-month and 36-month survival rates of 41% and 33%, respectively. The confirmed objective response rate was 21%.
The company announced a private placement led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals Inc. The deal offers approximately $85 million in upfront gross proceeds and up to an additional $255 million if warrants are exercised.
Strategic Shift to ROBBIN Trial
Proceeds will fund the planned registrational Phase 3 ROBBIN trial, evaluating the combination as a neoadjuvant treatment for high-risk Stage II and Stage III microsatellite-stable colon cancer. Agenus plans to discontinue financial support for its ongoing BATTMAN Phase 3 study. The first patient dose in ROBBIN is expected in the first quarter of 2027.
| Component | Shares / Warrants | Exercise Price |
|---|---|---|
| Common Stock / Pre-funded Warrants | 23,035,227 | $0.01 (if pre-funded) |
| Series A Purchase Warrants | 21,144,277 | $4.02 |
| Series B Purchase Warrants | 33,797,214 | $5.03 |
Stock Performance
On Tuesday, Agenus shares were down 7.60% at $5.66. The stock remains above its 20-day and 200-day simple moving averages, though the relative strength index indicates overbought territory.
What are the key milestones investors should watch for leading up to the ROBBIN trial launch in 2027?
How will the discontinuation of the BATTMAN Phase 3 study impact Agenus's overall pipeline diversification?
What are the potential market implications if the Series B warrants are exercised at the $5.03 strike price?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
